Targeting tsRNA-1797 Alleviates Diabetes-Induced Vascular Dysfunction Through Modulating Purine Metabolism
Diabetes · 01.07.2025 · 74 (7) · 1247-1261
DOI: 10.2337/db24-1158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, online erschienen am 24.04.2025. Verfasst von Duo Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Purines, Diabetes Mellitus, Experimental, Retinal Vessels. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Diabetes is a metabolic disorder associated with an increased risk of systemic vascular complications. Notably, diabetic retinopathy (DR) represents a major microvascular complication and a leading cause of blindness and vision impairment. Despite its clinical significance, the precise molecular mechanisms underlying vascular dysfunction and the associated metabolic disturbances in DR remain incompletely understood. In this study, we identified tsRNA-1797, a transfer RNA–derived small RNA, as a critical regulator of retinal vascular dysfunction. tsRNA-1797 expression was markedly upregulated under diabetic conditions. Functional studies demonstrated that silencing tsRNA-1797 ameliorated endothelial dysfunction in vitro and inhibited retinal vascular dysfunction in vivo. Mechanistically, tsRNA-1797 was found to disrupt purine metabolism by regulating adenosine production through CD73. The tsRNA-1797–CD73–adenosine axis emerged as a key mediator of retinal vascular dysfunction in DR. These findings establish tsRNA-1797 as a novel regulatory factor that links metabolic dysregulation to vascular dysfunction in DR, highlighting its potential as a promising therapeutic target for diabetes-induced vascular complications. Article Highlights tsRNA-1797 is a key regulator of diabetes-induced retinal vascular dysfunction. Overexpression of tsRNA-1797 exacerbates retinal vascular dysfunction in diabetes. tsRNA-1797 disrupts purine metabolism in retinal vascular endothelial cells. tsRNA-1797 directly targets CD73, reducing adenosine production and causing retinal vascular dysfunction in diabetic retinopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Affiliated Eye Hospital, Nanjing Medical University, Nanjing, China.
- Eye Institute and Department of Ophthalmology, Eye and ENT Hospital, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai, China.
- Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zitieren
APA
Li, D., Zhang, J., Han, X., Kong, L., Zhang, Y., Yao, M., Ren, L., Mu, W., Jiang, Q., & Yan, B. (2025). Targeting tsRNA-1797 Alleviates Diabetes-Induced Vascular Dysfunction Through Modulating Purine Metabolism. Diabetes, 74(7), 1247-1261. https://doi.org/10.2337/db24-1158
Vancouver
Li D, Zhang J, Han X, Kong L, Zhang Y, Yao M, et al. Targeting tsRNA-1797 Alleviates Diabetes-Induced Vascular Dysfunction Through Modulating Purine Metabolism. Diabetes. 2025;74(7):1247-1261. doi:10.2337/db24-1158
BibTeX
@article{Li2025,
author = {Li, Duo and Zhang, Jingyue and Han, Xiaoyan and Kong, Lingjie and Zhang, Ying and Yao, Mudi and Ren, Ling and Mu, Wan and Jiang, Qin and Yan, Biao},
title = {Targeting tsRNA-1797 Alleviates Diabetes-Induced Vascular Dysfunction Through Modulating Purine Metabolism},
journal = {Diabetes},
year = {2025},
volume = {74},
number = {7},
pages = {1247--1261},
doi = {10.2337/db24-1158}
}
EUVIMED